Listen to the most recent Podcasts developed by ESMO Open.
Immune-checkpoint inhibitors alone or in combination for the endometrial MMRd/MSI-H population
Molecular classification of endometrial cancer has changed the understanding of the distinct pathways underlying this heterogeneous cancer and paved the way to new therapeutic approaches. Mismatch repair deficient/microsatellite high (MMRd/MSI-H) tumours comprise up to 30% of cases. In this podcast Professors Nicoletta Colombo, of the Istituto Europeo di Oncologia IRCCS, Milan, Italy, and Florence Joly, of the Centre François-Baclesse, University of Caen Normandy, France, discuss existing and emerging treatment strategies incorporating immune checkpoint inhibitors with Dr Rita Canario, of Portuguese Oncology Institute of Porto, Porto, Portugal.
Published on 5 Mar 2024
First-line maintenance treatment of high grade serous ovarian cancer with a BRCA1/2 mutation
The best first-line maintenance treatment in a high grade serous ovarian cancer patient carrying a BRCA1/2 mutation is still up for debate. In this podcast Dr Margherita Turinetto, of the University of Turin, Italy, discusses the issues and data with Professor Isabelle Ray-Coquard, of the Centre Leon Berard, France, and Professor Charlie Gourley, Clinical Director, Cancer Research UK Scotland Centre, UK.
Published on 16 Feb 2024
A place for hormonal therapy in endometrial carcinoma?
Endometrial cancer is the most common gynaecological malignancy in developed nations, exhibiting rising incidence and mortality rates worldwide. In this podcast Dr Irene Giannubilo, of the Ospedale Policlinico San Martino, Genoa, Italy, discusses the possibilities for endocrine therapy for women with endometrial cancer with Professor Mansoor Raza Mirza, Copenhagen University Hospital, Denmark, and Professor Frederik Marmé, the University of Heidelberg Women's Hospital, Germany.
Published on 14 Feb 2024
Focus on systemic therapy for ovarian clear cell carcinoma
In this podcast, Dr Maria Kfoury, of Institut Paoli-Calmettes (IPC), Marseille, France, and Professor David Tan, of the National University Cancer Institute, Singapore, discuss developments in research in the systemic therapy of ovarian clear cell carcinoma: Are there any specific issues, and should they be treated separately?
Published on 31 Jan 2024
Surgery and HIPEC in relapse for all patients with Ovarian Cancer
Dr Shira Peleg Hasson, from The Royal Marsden NHS Foundation Trust, London, UK, leads a debate between Dr Philipp Harther (Kliniken Essen-Mitte, Essen, Germany) and Dr Christian Marth (Innsbruck Medical University, Austria) on he use of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer treatment.
Published in October 2023
ESMO Open podcast on phase II studies
ESMO Open Editor-in-Chief Professor Christoph Zielinski discusses with Dr Anna Berghoff the importance of phase II clinical trials to both the future of cancer research and the journal.
Published in November 2022
Anthracyclines for patients with early breast cancer - a debate
Dr Valentina Guarneri, of the istituto Oncologico Veneto, Padova, Italy, and Dr Evandro de Azambuja, of the Institut Jules Bordet and L’Université Libre de Bruxelles, Brussels, Belgium, discuss the pros and cons of treating patients with early breast cancer with anthracyclines.
Published in May 2022
Current highlights in lung cancer in 2021
There continues to be significant advances made in the field of lung cancer improving survival outcomes for patients. In this podcast, Dr Jonathan Lim (a member of the ESMO Young Oncologists Committee) discusses with Prof Ben Solomon (professor in thoracic medical oncology) for his highlights on lung cancer so far in 2021.
Published in July 2021
Application of the ESMO-MCBS (V.1.1) to the field of early breast cancer therapies
The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated value scale for solid tumour anticancer treatments. Form 1 of the ESMO-MCBS, used to grade therapies with curative intent including adjuvant therapies, has only been evaluated for a limited number of studies. This is the first large-scale field testing in early breast cancer to assess the applicability of the scale to this data set and the reasonableness of derived scores and to identify any shortcomings to be addressed in future modifications of the scale.Read the full article
Published in December 2020